Vaccine

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence EnhancerENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy…

3 months ago
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEOValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable…

3 months ago
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine…

3 months ago
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s DiseaseSerina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…

3 months ago
Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid ResearchRapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research

Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research

Burlington, Ontario--(Newsfile Corp. - April 8, 2025) -  Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech…

3 months ago
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer TherapiesDefence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),…

3 months ago
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United StatesTeva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome…

3 months ago
BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICSBREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA…

3 months ago
Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across CanadaRapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada

Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada

Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian…

3 months ago
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesPress Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm…

3 months ago